Download Files:
QNZ
$106 – $420
Products Details
Product Description
– QNZ (EVP4593) shows strong inhibitory effects on NF-κB transcriptional activation and TNF-α production with IC50s of 11 and 7 nM, respectively. QNZ (EVP4593) is a neuroprotective inhibitor of SOC channel.
Web ID
– HY-13812
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C22H20N4O
References
– [1]Tobe M, et al. Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B activation.|[2]Nekrasov ED, et al. Manifestation of Huntington’s disease pathology in human induced pluripotent stem cell-derived neurons. Mol Neurodegener. 2016 Apr 14;11:27.|[3]Wu J, et al. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington’s Disease Mouse Model. J Neurosci. 2016 Jan 6;36(1):125-41.
CAS Number
– 545380-34-5
Molecular Weight
– 356.42
Compound Purity
– 99.51
SMILES
– NC1=CC2=C(NCCC3=CC=C(OC4=CC=CC=C4)C=C3)N=CN=C2C=C1
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology; Neurological Disease
Solubility
– DMSO : ≥ 37 mg/mL
Target
– NF-κB;TNF Receptor
Isoform
– CD40;NF-κB
Pathway
– Apoptosis;NF-κB
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
